Methods for treating hybrid familial hypercholesterolemia (heFH) patients
By combining PCSK9 inhibitors with statins, the problem of existing treatments being unable to effectively control heterozygous familial hypercholesterolemia has been solved, resulting in a significant reduction in LDL-C and improvement in serum levels of various lipid components, thereby reducing the risk of cardiovascular disease.
Patent Information
- Application Number
- CN202610219438.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2015-03-23
- Filing Date
- 2015-07-16
- Publication Date
- 2026-06-02
AI Technical Summary
Current maximum tolerated dose statin therapy is ineffective in controlling low-density lipoprotein cholesterol levels in patients with heterozygous familial hypercholesterolemia, leading to an increased risk of cardiovascular disease.
PCSK9 inhibitors are used in combination with the maximum tolerated dose of statins, including antibodies that specifically bind to PCSK9 or their antigen-binding fragments, to treat patients with heterozygous familial hypercholesterolemia. This involves administering one or more doses of PCSK9 inhibitors to lower LDL cholesterol and improve serum levels of other lipid components.
Significantly reduces low-density lipoprotein cholesterol (LDL-C) by at least 40%, apolipoprotein B (ApoB) by at least 30%, non-high-density lipoprotein cholesterol (non-HDL-C) by at least 40%, total cholesterol by at least 20%, triglycerides by at least 5%, lipoprotein a (Lp(a)) by at least 20%, and increases high-density lipoprotein cholesterol (HDL-C) by at least 3% and apolipoprotein A1 by at least 1%.